1)Kaneko Y, Takeuchi T:A paradigm shift in rheumatoid arthritis over the past decade. Intern Med 53:1895-1903, 2014
2)Aletaha D, et al:2010 Rheumatoid arthritis classification criteria;An American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 62:2569-2581, 2010
3)Felson DT, et al:American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573-586, 2011
4)van Doornum S, et al:Accelerated atherosclerosis;An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862-873, 2002
5)van Nies JA, et al:What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73:861-870, 2014
6)Smolen JS, et al:Treating rheumatoid arthritis to target;2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3-15, 2016
7)McInnes IB, Schett G:The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219, 2011
8)Kaneko Y, Takeuchi T:Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis. Int Immunol 29:511-517, 2017
9)Kaneko Y:Efficacy and safety of peficitinib in rheumatoid arthritis. Mod Rheumatol 3:1-6, 2020
10)Takeuchi T, et al:Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70:1208-1215, 2011
11)Schett G, et al:How cytokine networks fuel inflammation;Toward a cytokine-based disease taxonomy. Nat Med 19:822-824, 2013